Reduce freezing through brain stimulation
- Trial ID
- NCT06505460
- Official Title
- Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study
- Goal
- Reduce freezing through brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- China Medical University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Transcranial Direct Current Stimulation
- Interventions
- Transcranial direct current stimulation
Plain-Language Summary
The goal is to reduce or better understand freezing of gait, the sudden, brief inability to step that many people with Parkinson's experience, especially during more challenging walking situations. The approach uses transcranial direct current stimulation, a gentle, non-invasive electrical current applied across the scalp to increase or decrease activity in brain regions that control walking, and compares effects in people with or without invasive neuromodulation like MR-guided focused ultrasound or deep brain stimulation while recording EEG and fMRI. tDCS is being tested as an add-on to usual treatments such as levodopa, not a replacement, and the team looks at how brain activity and gait change when medications are stable. About 20 adults aged 20 to 90 are being enrolled; eligible people include MRgFUS patients whose symptoms are not controlled by optimal medications and who have had stable meds for at least 30 days, and DBS patients with over 5 years of PD, clear levodopa responsiveness, and motor complications; exclusions include severe heart failure, metastatic cancer, Hoehn and Yahr stage 5, and for DBS candidates overt dementia or major depression.
Locations
- China Medical University Hospital/Neuro Depart, Taichung, Taiwan
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial direct current stimulation. The goal is to reduce or better understand freezing of gait, the sudden, brief inability to step that many people with Parkinson's experience, especially during more challenging walking situations. The approach uses transcranial direct current stimulation, a gentle, non-invasive electrical current applied across the scalp to increase or decrease activity in brain regions that control walking, and compares effects in people with or without invasive neuromodulation like MR-guided focused ultrasound or deep brain stimulation while recording EEG and fMRI. tDCS is being tested as an add-on to usual treatments such as levodopa, not a replacement, and the team looks at how brain activity and gait change when medications are stable. About 20 adults aged 20 to 90 are being enrolled; eligible people include MRgFUS patients whose symptoms are not controlled by optimal medications and who have had stable meds for at least 30 days, and DBS patients with over 5 years of PD, clear levodopa responsiveness, and motor complications; exclusions include severe heart failure, metastatic cancer, Hoehn and Yahr stage 5, and for DBS candidates overt dementia or major depression.
- Who can participate?
- Participants must be between 20 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 3 months.